Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 5/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GHSR | Q92847 | 9/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6441783 | 1.00 | CYP2C19 (0.45) | CYP2C19CYP2D6CYP2C9CYP3A4GHSR | |
| SCHEMBL6441464 | 0.91 | CYP2C19 (0.49) | CYP2C19CYP2D6CYP2C9CYP3A4GHSR | |
| SCHEMBL6441468 | 0.91 | CYP2C19 (0.49) | CYP2C19CYP2D6CYP2C9CYP3A4GHSR | |
| SCHEMBL6441395 | 0.89 | L3MBTL1 (0.39) | CYP2C19CYP2D6CYP2C9CYP3A4SMN1; SMN2 | |
| SCHEMBL6442547 | 0.87 | CYP2C19 (0.48) | CYP2C19CYP2D6CYP2C9CYP3A4GHSR | |
| SCHEMBL6442544 | 0.87 | CYP2C19 (0.48) | CYP2C19CYP2D6CYP2C9CYP3A4GHSR | |
| SCHEMBL6442629 | 0.84 | CYP2C19 (0.52) | CYP2C19CYP2D6CYP2C9CYP3A4GHSR | |
| SCHEMBL6442632 | 0.84 | CYP2C19 (0.52) | CYP2C19CYP2D6CYP2C9CYP3A4GHSR | |
| SCHEMBL6442483 | 0.84 | CYP2C19 (0.48) | CYP2C19CYP2D6CYP2C9CYP3A4GHSR | |
| SCHEMBL6442488 | 0.84 | CYP2C19 (0.48) | CYP2C19CYP2D6CYP2C9CYP3A4GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2002004440-A9 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2005-11-03 | — | — | WO | claimed |
| EP-1299382-B1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1299382-A4 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2004-02-11 | — | — | EP | claimed |
| US-6573262-B2 | Compounds for treating mammals infected with HIV virus | BRISTOL-MYERS SQIBB COMPANY | 2003-06-03 | — | — | US | claimed |
| US-20030069245-A1 | Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2003-04-10 | — | — | US | claimed |
| EP-1299382-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-09 | — | — | EP | claimed |
| WO-2002004440-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED INDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-01-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069245-A1 | Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives | IDO1, IDO2, ITPA | CYP2C19 1624/4885CYP2D6 831/4885CYP2C9 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.